Accelerated approval pathways help innovative treatments reach patients sooner, particularly in oncology and rare diseases where unmet medical needs are high.
From FDA Fast Track, Breakthrough Therapy, and Accelerated Approval to EMA Accelerated Assessment and Conditional Marketing Authorization, navigating these pathways requires strategic planning, robust evidence generation, and well-designed confirmatory studies.
Success isn't just about achieving approval faster; it's about balancing speed, science, compliance, and long-term patient benefit. Learn more from our blog: https://www.vigilarebp.com/blogs/accelerated-approval-pathways-explained-fda-ema-oncology-and-rare-disease-programs/














